Oppenheimer Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a ...
Regeneron Gets Court to Impose Tougher Kickback Standard (1)
Regeneron Pharmaceuticals Inc. convinced the First Circuit to impose a higher causation standard in the government’s False Claims Act case alleging a drug kickback scheme, according to a Tuesday ...
Hosted on MSN18h
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...